

February 3, 2021

Q3FY21 Result Update

☑ Change in Estimates | ☑ Target | ■ Reco

Change in Estimates

	Cui	rent	Prev	rious
	FY22E	FY23E	FY22E	FY23E
Rating	В	UY	В	UY
Target Price	1	82	1	69
Sales (Rs. m)	11,739	15,407	10,232	13,429
% Chng.	14.7	14.7		
EBITDA (Rs. m)	2,113	3,004	1,893	2,820
% Chng.	11.6	6.5		
EPS (Rs.)	7.9	11.8	6.9	10.9
% Chna.	14.5	7.6		

Key Financials - Standalone

Y/e Mar	FY20	FY21E	FY22E	FY23E
Sales (Rs. m)	8,463	9,030	11,739	15,407
EBITDA (Rs. m)	1,765	1,219	2,113	3,004
Margin (%)	20.8	13.5	18.0	19.5
PAT (Rs. m)	1,310	789	1,300	1,948
EPS (Rs.)	7.9	4.8	7.9	11.8
Gr. (%)	(28.9)	(39.8)	64.9	49.8
DPS (Rs.)	1.8	1.1	1.8	2.7
Yield (%)	1.2	0.7	1.3	1.9
RoE (%)	11.2	6.5	10.1	13.8
RoCE (%)	13.2	8.4	13.6	18.5
EV/Sales (x)	2.8	2.5	1.8	1.2
EV/EBITDA (x)	13.2	18.6	10.0	6.2
PE (x)	18.1	30.0	18.2	12.1
P/BV (x)	2.0	1.9	1.8	1.6

Key Data	NOCI.BO NOCIL IN
52-W High / Low	Rs.164 / Rs.45
Sensex / Nifty	49,798 / 14,648
Market Cap	Rs.24bn/\$ 325m
Shares Outstanding	166m
3M Av g. Daily Value	Rs.427.2m

Shareholding Pattern (%)

Promoter's	33.96
Foreign	2.05
Domestic Institution	5.09
Public & Others	58.90
Promoter Pledge (Rs bn)	0.68

Stock Performance (%)

	1M	6M	12M
Absolute	(4.9)	35.9	60.0
Relative	(8.6)	2.6	27.6

Avishek Datta

avishekdatta@plindia.com | 91-22-66322254

NOCIL (NOCIL IN)

Rating: BUY | CMP: Rs143 | TP: Rs182

Impressive growth commentary

Quick Pointers:

- Impressive volume growth of 25%QoQ in Q3FY21. Management increased FY21 volume/sales guidance 8-10% vs flat earlier, despite Q1 washout.
- Price hikes taken in Jan-21 in order to pass on high RM prices and improve margins ahead.
- Volume maximization at the cost of margins will be new strategygoing forward.

We increase our volume assumptions but lower our margin estimates and accordingly FY21-23E estimates increase by 7-14%. Demand environment improved in domestic and international markets, given strong tyre demand coupled with improving pricing environment augurs well for the space. Nocil, with new capacities commissioned is poised to benefit from recovery in auto demand. Reiterate BUY with a TP of Rs182 (Rs169) based on 15x PER FY23E.

- Volume growth of 25%QoQ is impressive: Nocil reported Q3FY21 EBITDA and PAT of Rs369mn (+3% YoY; PLe Rs 425mn) and Rs221mn (+7% YoY; PLe -Rs256mn), respectively. Q3 revenues were at Rs2.7bn (+24%QoQ) and included volume growth of 25%QoQ. EBIDTA margins came down to 13.4% (20.8%% in FY20) as gross margins came down to 43.4% (48.1% in Q2FY21). For FY21, management is confident of 8-10%YoY volume/sales growth (earlier flat volumes) despite Q1 washout, which is impressive in our view.
- Gross margins come off: For Q3, gross margins were at 43.4% as the company purchased RM (which were at unprecedented levels) to meet incremental demand. Company has since passed on RM prices effective January and expect margins to improve QoQ. Also, management has reiterated GM of 50% over the medium term. We factor in gross margins of 46%/50%/50% for FY21/22/23E vs 54.2% in FY20. Volume maximization strategy is in line with China Sunsine policy which prioritizes volumes. We remain structurally positive on the company as Nocil remains a play on operating leverage in a recovering demand environment.
- Opportunities galore: Nocil is one of the largest rubber chemicals player globally with capacity of 110,000tons (currently 90,000tons) including intermediaries. Rising clamor to diversify supplies awayfrom China can open many opportunities for Nocil. Also, limited capacity addition by global players, ex Chinese, will mean Nocil is well placed to capitalize on any demand recovery.



Exhibit 1: Q3FY21 Result Overview (Rs mn)

Y/e March	Q3FY21	Q3FY20	Yo Y gr. (%)	Q2FY21	9MFY21	9MFY20	Yo Y gr. (%)
Income From Operations	2,746	1,943	41.3	2,216	6,027	6,336	(4.9)
Total Expenditure							
Cost of Material Consumed	1,339	809	65.6	1,206	2,942	2,689	9.4
Purchase of stock in trade	7	6	19.7	3	26	20	28.7
Change in inventory of FG, WIP and SIT	207	113	84.2	(60)	297	107	178.3
Total RM Cost	1,554	927	67.6	1,150	3,265	2,816	16.0
Gross Margin	1,192	1,016	17.3	1,066	2,762	3,521	(21.5)
Margin (%)	43.4	52.3		48.1	<i>4</i> 5.8	55.6	
Employee Cost	175	187	(6.4)	173	507	567	(10.5)
Other Expense	648	472	37.4	581	2,085	1,557	33.9
Other Expense (%)	0	0		0	1	1	
Excise	-	-		-	-	-	
Total Expenditure	2,377	1,586	49.8	1,904	6,698	4,939	35.6
EBIDTA	369	357	3.4	312	756	1,397	(45.9)
% of NS	13.4	18.4		14.1	12.5	22.1	
Depreciation	88	79	10.6	88	324	233	39.3
EBIT	281	278	1.3	224	493	1,165	(57.7)
Interest	2	3	(25.0)	3	8	10	(22.7)
Other Income	16	13	23.4	9	97	62	55.7
Exceptional Items	-	-		-	-	-	
PBT	295	287	2.6	231	616	1,217	(49.4)
Tax	74	81	(8.3)	64	214	131	63.3
Tax rate %	25.1	28.1		27.8	34.8	10.8	
Profit After Tax	221	207	6.8	167	505	1,086	(53.5)

Source: Company, PL

Conference Call Highlights: Strong volume guidance along with price hikes to drive earnings

- Management expects sales & volume growth of 8-10% for FY21 vs earlier expectation of flat growth.
- Q3 volume growth of 25%QoQ and expects strong volumes for Q4.
- Gross margins contraction in Q3 because of requirement to buy spot volumes for meeting incremental demand.
- There has been unprecedented rise in RM prices in Q3 and company has started taking price hikes from January to partly correct this; mgt expect GM to improve in Q4. Also company expects RM to correct.
- Company remains confident of achieving GM of 50% in medium term.
- Company expects full utilization of new capacity by Sept 23 vs earlier est. of Mar 24.
- Interim duty protection under ADD was not approved by govt but investigations are on and final decision is expected by May21.



Financials

Income Statement (Rs m)

Income Statement (Rs m)				
Y/e Mar	FY20	FY21E	FY22E	FY23E
Net Revenues	8,463	9,030	11,739	15,407
YoY gr. (%)	(18.9)	6.7	30.0	31.3
Cost of Goods Sold	3,879	4,876	5,870	7,704
Gross Profit	4,585	4,154	5,870	7,704
Margin (%)	54.2	46 .0	50.0	50.0
Employ ee Cost	741	813	1,057	1,233
Other Expenses	2,079	2,122	2,700	3,467
EBITDA	1,765	1,219	2,113	3,004
YoY gr. (%)	(39.2)	(30.9)	73.3	42.2
Margin (%)	20.8	13.5	18.0	19.5
Depreciation and Amortization	324	354	450	484
EBIT	1,440	865	1,663	2,520
Margin (%)	17.0	9.6	14.2	16.4
Net Interest	13	12	5	5
Other Income	97	145	81	89
Profit Before Tax	1,524	998	1,739	2,604
Margin (%)	18.0	11.1	14.8	16.9
Total Tax	214	210	438	656
Effective tax rate (%)	14.1	21.0	25.2	25.2
Profit after tax	1,310	789	1,300	1,948
Minority interest	-	-	-	-
Share Profit from Associate	-	-	-	-
Adjusted PAT	1,310	789	1,300	1,948
YoY gr. (%)	(28.9)	(39.8)	64.9	49.8
Margin (%)	15.5	8.7	11.1	12.6
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	1,310	789	1,300	1,948
YoY gr. (%)	(28.9)	(39.8)	64.9	49.8
Margin (%)	15.5	8.7	11.1	12.6
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	1,310	789	1,300	1,948
Equity Shares O/s (m)	166	166	166	166
EPS (Rs)	7.9	4.8	7.9	11.8

Source: Company Data, PL Research

Balance Sheet Abstract (Rs	m)			
Y/e Mar	FY20	FY21E	FY22E	FY23E
Non-Current Assets				
Gross Block	9,812	10,013	11,713	12,413
Tangibles	9,812	10,013	11,713	12,413
Intangibles	-	-	-	-
Acc: Dep / Amortization	2,130	2,483	2,933	3,417
Tangibles	2,130	2,483	2,933	3,417
Intangibles	-	-	-	-
Net fixed assets	7,683	7,530	8,780	8,996
Tangibles	7,683	7,530	8,780	8,996
Intangibles	-	-	-	-
Capital Work In Progress	1,563	1,576	150	150
Goodwill	12	13	15	16
Non-Current Investments	551	590	590	590
Net Deferred tax assets	(887)	(913)	(1,087)	(1,347)
Other Non-Current Assets	301	224	236	250
Current Assets				
Investments	232	280	280	280
Inv entories	1,361	1,335	1,736	2,279
Trade receivables	2,032	2,133	2,772	3,639
Cash & Bank Balance	128	644	2,346	4,610
Other Current Assets	405	261	287	316
Total Assets	14,279	14,597	17,205	21,139
Equity				
Equity Share Capital	1,656	1,656	1,656	1,656
Other Equity	10,104	10,681	11,680	13,178
Total Networth	11,760	12,337	13,337	14,834
Non-Current Liabilities				
Long Term borrowings	-	-	-	-
Provisions	163	156	187	225
Other non current liabilities	1	1	1	1
Current Liabilities				
ST Debt / Current of LT Debt	-	-	-	-
Trade payables	892	997	1,296	1,700
Other current liabilities	507	375	446	533

14,279

14,835

16,353

18,639

Source: Company Data, PL Research

Total Equity & Liabilities

February 3, 2021 3



Cash Flow (Rs m)				
Y/e Mar	FY20	FY21E	FY22E	FY23E
PBT	1,524	998	1,739	2,604
Add. Depreciation	324	354	450	484
Add. Interest	13	12	5	5
Less Financial Other Income	97	145	81	89
Add. Other	(65)	97	193	284
Op. profit before WC changes	1,796	1,462	2,386	3,377
Net Changes-WC	407	40	(698)	(947)
Direct tax	(214)	(210)	(438)	(656)
Net cash from Op. activities	1,989	1,292	1,250	1,774
Capital expenditures	(1,986)	(215)	(275)	(701)
Interest / Dividend Income	-	-	-	-
Others	761	(87)	-	-
Net Cash from Invt. activities	(1,225)	(302)	(275)	(701)
Issue of share cap. / premium	2	10,917	(89)	(150)
Debt changes	-	-	-	-
Dividend paid	(494)	(350)	(212)	(301)
Interest paid	(13)	(12)	(5)	(5)
Others	-	-	-	-
Net cash from Fin. activities	(506)	10,555	(306)	(456)
Net change in cash	258	11,544	669	616
Free Cash Flow	3	1,076	975	1,072

Source: Company Data, PL Research

Quarterly Financials (Rs m) Y/e Mar

Y/e Mar	Q4FY20	Q1FY21	Q2FY21	Q3FY21
Net Revenue	2,127	1,065	2,216	2,746
YoY gr. (%)	(12.0)	(53.6)	5.7	41.3
Raw Material Expenses	1,063	547	1,150	1,554
Gross Profit	1,064	518	1,066	1,192
Margin (%)	50.0	48.6	48.1	43.4
EBITDA	367	75	312	369
YoY gr. (%)	(37.8)	(86.7)	(34.8)	3.4
Margin (%)	17.3	7.0	14.1	13.4
Depreciation / Depletion	92	88	88	88
EBIT	276	(13)	224	281
Margin (%)	13.0	(1.2)	10.1	10.2
Net Interest	4	3	3	2
Other Income	35	106	9	16
Profit before Tax	307	91	231	295
Margin (%)	14.4	8.5	10.4	10.7
Total Tax	83	(27)	64	74
Effective tax rate (%)	27.0	(29.7)	27.8	25.1
Profit after Tax	224	118	167	221
Minority interest	-	-	-	-
Share Profit from Associates	-	-	-	-
Adjusted PAT	224	118	167	221
YoY gr. (%)	(37.4)	(64.0)	(69.8)	6.8
Margin (%)	10.5	11.0	7.5	8.0
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	224	118	167	221
YoY gr. (%)	(37.4)	(64.0)	(69.8)	6.8
Margin (%)	10.5	11.0	7.5	8.0
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	224	118	-	-
Av g. Shares O/s (m)	-	-	-	-
EPS (Rs)	-	-	-	-

Source: Company Data, PL Research

Key Financial Metrics				
Y/e Mar	FY20	FY21E	FY22E	FY23E
Per Share(Rs)				
EPS	7.9	4.8	7.9	11.8
CEPS	9.9	6.9	10.6	14.7
BVPS	71.0	74.5	80.5	89.6
FCF	0.0	6.5	5.9	6.5
DPS	1.8	1.1	1.8	2.7
Return Ratio(%)				
RoCE	13.2	8.4	13.6	18.5
ROIC	12.4	8.4	12.3	14.2
RoE	11.2	6.5	10.1	13.8
Balance Sheet				
Net Debt : Equity (x)	0.0	(0.1)	(0.2)	(0.3)
Net Working Capital (Days)	108	100	100	100
Valuation(x)				
PER	18.1	30.0	18.2	12.1
P/B	2.0	1.9	1.8	1.6
P/CEPS	14.5	20.7	13.5	9.7
EV/EBITDA	13.2	18.6	10.0	6.2
EV/Sales	2.8	2.5	1.8	1.2
Dividend Yield (%)	1.2	0.7	1.3	1.9

Source: Company Data, PL Research





Analyst Coverage Universe

	Coverage Universe	D. C.	TD (D.)	OL D: (D.)
Sr. No.	Company Name	Rating	TP (Rs)	Share Price (Rs)
1	Aarti Industries	BUY	1,314	1,159
2	Bharat Petroleum Corporation	BUY	479	392
3	GAIL (India)	UR	-	133
4	Gujarat Gas	BUY	403	387
5	Hindustan Petroleum Corporation	BUY	280	223
6	Indian Oil Corporation	BUY	124	96
7	Indraprastha Gas	BUY	603	540
8	Mahanagar Gas	BUY	1,275	1,117
9	NOCIL	BUY	169	253
10	Oil & Natural Gas Corporation	BUY	114	98
11	Oil India	Accumulate	117	113
12	Petronet LNG	BUY	399	260
13	Reliance Industries	BUY	2,232	2,050

PL's Recommendation Nomenclature (Absolute Performance)

 Buy
 : > 15%

 Accumulate
 : 5% to 15%

 Hold
 : +5% to -5%

 Reduce
 : -5% to -15%

 Sell
 : < -15%</td>

Not Rated (NR) : No specific call on the stock
Under Review (UR) : Rating likely to change shortly



ANALYST CERTIFICATION

(Indian Clients)

We/I, Mr. Av ishek Datta- MBA Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

(US Clients)

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that. All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

DISCLAIMER

Indian Clients

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd. which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at www.plindia.com.

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is in the process of applying for certificate of registration as Research Analyst under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months.

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report. PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Avishek Datta- MBA Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

US Clients

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Poloor another U.S. registered broker dealer.

Prabhudas Lilladher Pvt. Ltd.

3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018, India | Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209 www.plindia.com